Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to $8.1 million.

  • Amicus Therapeutics' Change in Receivables fell 646.77% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 2401.87%. This contributed to the annual value of $19.5 million for FY2024, which is 310.32% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Change in Receivables is $8.1 million, which was down 646.77% from $12.5 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Change in Receivables high stood at $12.5 million for Q2 2025, and its period low was -$15.3 million during Q1 2025.
  • For the 5-year period, Amicus Therapeutics' Change in Receivables averaged around $3.7 million, with its median value being $3.4 million (2022).
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 61006.56% in 2021, then crashed by 79912.22% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Change in Receivables (Quarter) stood at $1.8 million in 2021, then surged by 445.07% to $9.9 million in 2022, then increased by 16.05% to $11.5 million in 2023, then dropped by 9.57% to $10.4 million in 2024, then decreased by 22.22% to $8.1 million in 2025.
  • Its Change in Receivables stands at $8.1 million for Q3 2025, versus $12.5 million for Q2 2025 and -$15.3 million for Q1 2025.